ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the European Commission has adopted a decision granting EU marketing authorisation (MA) for ECOVAXXIN® MS, the Company’s poultry vaccine against Mycoplasma synoviae.

The MA has been issued over a month earlier than anticipated following the Committee for Medicinal Products for Veterinary Use’s Positive Opinion in November 2025.

ECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synoviae infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.

The Company will issue an update to the market in early 2026 to provide further details on its plans for the EU commercial launch of ECOVAXXIN® MS.

David Hallas, Chief Executive Officer of ECO Animal Health, said: “We are delighted to have received EU marketing authorisation for ECOVAXXIN MS, over a month ahead of schedule. This is a key milestone for ECO, enabling the first commercial launch from our innovative R&D portfolio, and reflects the high-quality work from our R&D, regulatory, marketing, and technical teams.

“We look forward to updating the market early in 2026 to provide more detail on our plans for the commercial launch of this important vaccine.”